Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Item
http://www.wikidata.org/entity/Q39512836
Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cellsTherapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosisChildhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.Imatinib in neurofibromatosis type 2.Targeting the PDGF signaling pathway in tumor treatmentNeurofibromatosis-related tumors: emerging biology and therapies.Role of Merlin/NF2 inactivation in tumor biology.Merlin, a multi-suppressor from cell membrane to the nucleus.Schwannomas and their pathogenesis.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cellsThe role of insulin-like growth factors signaling in merlin-deficient human schwannomas.Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2
P2860

Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Item
http://www.wikidata.org/entity/Q39512836
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Nilotinib alone or in combinat ...... for neurofibromatosis type 2.
@en
Nilotinib alone or in combinat ...... for neurofibromatosis type 2.
@nl
type
label
Nilotinib alone or in combinat ...... for neurofibromatosis type 2.
@en
Nilotinib alone or in combinat ...... for neurofibromatosis type 2.
@nl
prefLabel
Nilotinib alone or in combinat ...... for neurofibromatosis type 2.
@en
Nilotinib alone or in combinat ...... for neurofibromatosis type 2.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Nilotinib alone or in combinat ...... e for neurofibromatosis type 2
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932